PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30651971-1	2019	Background: Previously, we have demonstrated that IL-33 administration protecting TNBS-induced experimental colitis is associated with facilitation of Th2/Tregs responses in mice.	Trinitrobenzenesulfonic Acid	82-86	interleukin 33	Mus musculus	50-55	
30651971-10	2019	Conclusions: IL-33 regulates the autophagy is a new immunoregulatory property on TNBS-induced experimental colitis in mice.	Trinitrobenzenesulfonic Acid	81-85	interleukin 33	Mus musculus	13-18	
22426954-4	2012	We found that IL-33 levels were increased in the TNBS-treated mice, whereas recombinant IL-33 (rIL-33) administration substantially ameliorated TNBS-mediated colonic tissue injury and clinical symptoms of colitis.	Trinitrobenzenesulfonic Acid	49-53	interleukin 33	Mus musculus	14-19	
22426954-4	2012	We found that IL-33 levels were increased in the TNBS-treated mice, whereas recombinant IL-33 (rIL-33) administration substantially ameliorated TNBS-mediated colonic tissue injury and clinical symptoms of colitis.	Trinitrobenzenesulfonic Acid	144-148	interleukin 33	Mus musculus	88-93	
22426954-6	2012	Importantly, rIL-33 treatment resulted in prominently upregulated Foxp3 expression in the TNBS-treated mice, and depletion of Tregs significantly abrogated the impact of IL-33 on reducing the development of colitis.	Trinitrobenzenesulfonic Acid	90-94	interleukin 33	Mus musculus	14-19